A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating Efficacy, Safety, and Pharmacokinetics of Crovalimab in Patients With Antiphospholipid Syndrome (APS)
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Crovalimab (Primary) ; Vitamin K antagonists (Primary)
- Indications Antiphospholipid syndrome
- Focus Therapeutic Use
- Sponsors Roche
Most Recent Events
- 02 Mar 2026 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: The study was discontinued due to a strategic business/portfolio decision by the sponsor and was not related to any medical or safety issue.
- 17 Nov 2025 Planned initiation date changed from 5 Dec 2025 to 16 Mar 2026.
- 19 Sep 2025 New trial record